Literature DB >> 20831290

Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.

Isao Kamae1.   

Abstract

Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st century. Whilst Japan has seen very limited use of health technology assessment (HTA), South Korea, Taiwan and Thailand have had remarkable success in establishing government agencies for HTA, employing HTA concepts from the UK National Institute for Health and Clinical Excellence (NICE). These three countries are driven by the following common factors: (i) a desire to establish universal healthcare insurance coverage in their respective nations; (ii) the need for rational allocation of scarce resources; (iii) a desire for government to provide leadership in HTA; and (iv) availability of HTA professionals and faculties through international networks. The HTA models introduced by these three countries are both similar to and different from those of HTA agencies in Europe, but might work well as examples for other countries in the region.

Mesh:

Year:  2010        PMID: 20831290     DOI: 10.2165/11538360-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  17 in total

1.  Health economic evaluation in Japan: a case study of one aspect of health technology assessment.

Authors:  Adam Oliver
Journal:  Health Policy       Date:  2003-02       Impact factor: 2.980

Review 2.  What is next for pharmacoeconomics and outcomes research in Asia?

Authors:  Jim Doherty; Isao Kamae; Kenneth K C Lee; Hong Li; Shu-Chun Li; Gordon G Liu; Yen-Huei Tarn; Bong-min Yang
Journal:  Value Health       Date:  2004 Mar-Apr       Impact factor: 5.725

Review 3.  Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.

Authors:  Thidaporn Jirawattanapisal; Pritaporn Kingkaew; Tae-Jin Lee; Ming-Chin Yang
Journal:  Value Health       Date:  2009 Nov-Dec       Impact factor: 5.725

4.  Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.

Authors:  Eun Young Bae; Eui Kyung Lee
Journal:  Value Health       Date:  2009 Nov-Dec       Impact factor: 5.725

Review 5.  Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations.

Authors:  Kun-Sei Lee; Werner B F Brouwer; Sang-Il Lee; Hye-Won Koo
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  Health technology assessment agencies: an international overview of organizational aspects.

Authors:  Francesco Martelli; Giuseppe La Torre; Elena Di Ghionno; Tommaso Staniscia; Massimo Neroni; Americo Cicchetti; Konrade Von Bremen; Walter Ricciardi
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

7.  Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.

Authors:  Bong-min Yang; Eun-young Bae; Jinhyun Kim
Journal:  Health Aff (Millwood)       Date:  2008 Jan-Feb       Impact factor: 6.301

8.  The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.

Authors:  William F McGhan; Maiwenn Al; Jalpa A Doshi; Isao Kamae; Steven E Marx; Donna Rindress
Journal:  Value Health       Date:  2009-09-10       Impact factor: 5.725

9.  Will the cost curve bend, even without reform?

Authors:  David M Cutler
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

10.  The future of health technology assessment in healthcare decision making in Asia.

Authors:  Bong-Min Yang
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more
  7 in total

1.  Perspectives on comparative effectiveness research: views from diverse constituencies.

Authors:  Dave Nellesen; Howard G Birnbaum; Paul E Greenberg
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

Review 3.  The evolution of Taiwan's National Health Insurance drug reimbursement scheme.

Authors:  Jason C Hsu; Christine Y Lu
Journal:  Daru       Date:  2015-02-10       Impact factor: 3.117

Review 4.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

5.  Value-based healthcare translated: a complementary view of implementation.

Authors:  Christian Colldén; Andreas Hellström
Journal:  BMC Health Serv Res       Date:  2018-09-03       Impact factor: 2.655

6.  Healthcare Databases in Thailand and Japan: Potential Sources for Health Technology Assessment Research.

Authors:  Surasak Saokaew; Takashi Sugimoto; Isao Kamae; Chayanin Pratoomsoot; Nathorn Chaiyakunapruk
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

7.  An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".

Authors:  Jing Pang; Miao Hu; Jie Lin; Takashi Miida; Hapizah M Nawawi; Jeong Euy Park; Xue Wu; Anis S Ramli; Ngoc Thanh Kim; See Kwok; Lourdes E Gonzalez-Santos; Ta-Chen Su; Thanh Huong Truong; Handrean Soran; Shizuya Yamashita; Brian Tomlinson; Gerald F Watts
Journal:  BMJ Open       Date:  2017-10-25       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.